Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
3(60%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_4
1
20%
Ph phase_1
1
20%
Ph phase_3
2
40%
Ph phase_2
1
20%

Phase Distribution

1

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
2(40.0%)
Phase 4Post-market surveillance
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

5

all time

Status Distribution
Active(3)
Completed(2)

Detailed Status

Completed2
Recruiting2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
3
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (20.0%)
Phase 21 (20.0%)
Phase 32 (40.0%)
Phase 41 (20.0%)

Trials by Status

active_not_recruiting120%
completed240%
recruiting240%

Recent Activity

3 active trials
Showing 5 of 5
active_not_recruitingphase_3

A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

NCT06081894
recruitingphase_4

Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy

NCT07600177
recruitingphase_2

A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

NCT06412666
completedphase_3

An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM

NCT06116968
completedphase_1

Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval

NCT05924815

Clinical Trials (5)

Showing 5 of 5 trials
NCT06081894Phase 3

A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

Active Not Recruiting
NCT07600177Phase 4

Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy

Recruiting
NCT06412666Phase 2

A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

Recruiting
NCT06116968Phase 3

An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM

Completed
NCT05924815Phase 1

Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5